Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Aaron S. Mansfield(Mayo Clinic), Keith T. Flaherty(Cancer Research Center), Noeen Malik(Stanford University), Lyndsay N. Harris(National Institutes of Health), Elad Sharon(National Cancer Institute), Peter J. O’Dwyer(University of Pennsylvania), Larry Rubinstein(National Cancer Institute), David R. Patton(National Cancer Institute), Lisa M. McShane(National Cancer Institute), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Ranee Mehra(University of Maryland, Baltimore), A. P. Chen(National Cancer Institute), Barbara A. Conley(National Cancer Institute), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Alexander Drilon(Memorial Sloan Kettering Cancer Center), Scott A. Tomlins(Stratasys (Israel)), Robert J. Gray(University of Glasgow), Stanley R. Hamilton(City of Hope), Alice T. Shaw(Dana-Farber Cancer Institute), Naoko Takebe(National Cancer Institute), Edith P. Mitchell(Thomas Jefferson University Hospital), Daniel H. Hovelson(Michigan Medicine), Zihan Wei(The People's Hospital of Guangxi Zhuang Autonomous Region), S. Li(Dana-Farber Cancer Institute), P. Mickey Williams(Leidos (United States)), James R. Wright(Duke University), Kelsey Poorman(Caris Life Sciences (United States)), Jia-Hui Zeng(Caris Life Sciences (United States)), Christopher H. Lieu(University of Colorado Denver)
Cited by 42
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k